3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors

A compound of Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• each of X1 and X2 is independently N or S, with the proviso that X1 and X2 are not simultaneously S;
• L1 is selected from the group consisting of —N(R)—, —N(R)—C(═O)—N(R)—, —O—C(═O)—N(R)—, —N(R)—C(═O)— and —C(═O)—N(R)—;
• L2 is selected from the group consisting of a covalent bond, —N(R)—, —N(R)—C(═O)—, —C(═O)—N(R)— and —N(R)—C(═O)—N(R)—;
• each R independently is H or C1-6 alkyl;
• each R1 independently is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, halogen, and OR;
• or wherein two adjacent R1 groups taken together with the carbon atoms to which they are attached form a six-membered aryl or a five- or six-membered heteroaryl;
• n is 0, 1, or 2;
• R2 is selected from the group consisting of:
• a) H;
• b) C1-6 alkyl that is unsubstituted or substituted with one or two substituents selected from the group consisting of heterocyclyl, —C(═O)OR, hydroxy, O1-6 alkoxy, and aryl;
• and
• and
• R3 is selected from the group consisting of H, hydroxy, —NO2, aryl, and heteroaryl, wherein said aryl or heteroaryl is unsubstituted or substituted with one to three substituents selected from the group consisting of halo, C1-6 haloalkyl, and C1-6 alkyl.